LN Investors • Thu, Sep. 25
Sirtex Medical May Have Amazing Expansion In 2015 For Liver Cancer Treatment ProductLN Investors • Thu, Sep. 25
- Specialized medical treatment targets liver cancer cells, leaving healthy tissue unaffected.
- SIR-Spheres microspheres product may go from "salvage" to "first line" treatment, expanding its usage for many more liver cancer patients.
- Clinical trial results which may show product should be a first-line treatment expected in 2015.
- Company begins preparing for the potentially dramatic increase in demand and production.
There are no Transcripts on SXMDF.
We currently have no Breaking News on this stock.
SXMDF vs. ETF Alternatives
Other News & PR